Vincent Michael Lawton - 02 Sep 2026 Form 4 Insider Report for Addex Therapeutics Ltd. (ADXN)

Reporting relationship: Director
Issuer ticker: ADXN
Reported as of: 02 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Sep 2026, 16:02:09 UTC
Prior SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Lenaic Nathanael Teyssedou by power of attorney

Key filing fact

Vincent Michael Lawton filed Form 4 for Addex Therapeutics Ltd. (ADXN) on 04 Sep 2026.

Key facts

This page summarizes Vincent Michael Lawton's Form 4 filing for Addex Therapeutics Ltd. (ADXN).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Sep 2026, 16:02.

Change

Previous filing in this sequence was filed on 25 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002123870 Primary reporting owner

Lawton Vincent Michael

Relationship: Director
Address: CHEMIN DES MINES 9, GENEVA, SWITZERLAND
Signature: /s/ Lenaic Nathanael Teyssedou by power of attorney
Signature date: 04 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADXN transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -2,507,487
Change %: -100%
Price: $0.000000^*
Shares after: 500
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1

ADXN transaction

Common Stock

Award

Transaction value
Shares: +2,507,487
Change %: +501497%
Price: $0.000000^*
Shares after: 2,507,987
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADXN transaction Derivative

Stock-option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -501,598
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 501,598
Exercise price: $0.0620
Footnotes: F2, F3

ADXN transaction Derivative

Stock-option (Right to Buy)

Award

Transaction value
Shares: +501,598
Change %
Price: $0.000000^*
Shares after: 501,598
Date: 02 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 501,598
Exercise price: $0.0320
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents 2,507,487 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 1,464,334 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 1,043,153 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.

Footnote F2

On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.

Footnote F3

The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.